Test Price
2,000 AEDโ Home Collection Available
Cancer Breast Comprehensive Panel โ 1,500 AED
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing using multi-modal tissue analysis.
Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival tissue blocks (FFPE). Hospital extraction only โ sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with oncology specialists.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Cancer Breast Comprehensive Panel is a definitive tissue-based biomarker assay combining Immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki-67, with Fluorescence In-Situ Hybridization (FISH) for HER2 gene amplification, and PCR-based Microsatellite Instability (MSI) analysis. This integrated evaluation drives accurate oncologic subtyping and personalized therapeutic decisions.
| Feature | Our Cancer Breast Comprehensive Panel | Closest Alternative |
|---|---|---|
| Precision | Multi-marker IHC + FISH + MSI | IHC-only or single-gene test |
| Methodology | Automated tissue pathology platforms (IHC, FISH, PCR) | Manual or limited assay |
| Turnaround Time | 10 working days | 14โ21 days |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011) advises: โBreast cancer biomarker results must be correlated with clinical and imaging findings. A negative IHC for HER2 does not exclude gene amplification โ reflex FISH ensures diagnostic accuracy. Always discuss any treatment modification with your oncologist.โ
Advisory & Medication Warning
Do not discontinue prescribed medication without consulting your doctor. All clinical decisions must be based on the full pathology report and clinical context.
Exclusion Criteria & Emergency Red Flags
- Active bleeding or purulent infection at the biopsy site.
- Known allergy to local anesthetics (if repeat biopsy required).
- Inadequate sample without cold chain transport โ may compromise accuracy.
- Patients under 18 years: mandatory parental/legal guardian consent in accordance with UAE Federal Law No. 2 of 2019.
- Seek immediate medical attention if you experience new breast lump, skin dimpling, nipple discharge, or persistent pain.
Patient FAQ & Clinical Guidance
1. What does the Cancer Breast Comprehensive Panel detect?
The panel pinpoints your tumor's hormone receptor status, HER2 amplification, and microsatellite instability โ key molecular drivers for targeted therapy and prognosis assessment.
2. When will I receive the results, and how is the sample collected?
Results are reported within 10 working days. Samples are archival tissue specimens (FFPE blocks or slides) collected via Secure Medical Courier Solid Tissue Specimen Retrieval from the referring hospital or pathology laboratory.
3. Will UAE health insurance cover this comprehensive breast cancer panel?
We offer direct billing verification via WhatsApp (+971 54 548 8731); most UAE insurers reimburse comprehensive cancer diagnostics aligned with DHA protocols.
UAE Regulatory & Data Privacy Adherence
Data Privacy: All patient data is processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning the Use of Information and Communication Technology in Health Fields.
Medical Liability: Clinical testing and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditation: ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Institutional Oversight: DNA Labs UAE, DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | Cancer Breast Comprehensive Panel |
| Price (AED) | 1,500 |
| Turnaround Time | 10 working days |
| Sample Type / Matrix | Archival Tissue โ Formalin-fixed paraffin-embedded (FFPE) tissue block or slides |
| Methodology Used | Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and PCR-based Microsatellite Instability (MSI) analysis |
| ICD-10-CM Code | C50.9 โ Malignant neoplasm of breast, unspecified |
| LOINC Code | 74774-5 โ Breast cancer comprehensive panel |
| DHA Facility License & Laboratory Address | License No. 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians